Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have covered the stock in the last year is $17.33.

A number of analysts recently weighed in on TNYA shares. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Tuesday. Leerink Partners reiterated an "outperform" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital restated a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Piper Sandler restated an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research report on Friday, October 18th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. lifted its holdings in Tenaya Therapeutics by 204.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company's stock worth $651,000 after buying an additional 226,466 shares during the last quarter. abrdn plc acquired a new stake in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $1,063,000. State Street Corp raised its position in shares of Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company's stock worth $2,044,000 after purchasing an additional 9,506 shares during the period. XTX Topco Ltd raised its position in shares of Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company's stock worth $95,000 after purchasing an additional 16,687 shares during the period. Finally, Geode Capital Management LLC increased its position in Tenaya Therapeutics by 5.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company's stock valued at $2,502,000 after acquiring an additional 66,968 shares during the period. Hedge funds and other institutional investors own 90.54% of the company's stock.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded down $0.08 during trading hours on Monday, reaching $1.39. 1,585,972 shares of the stock were exchanged, compared to its average volume of 2,252,076. The stock has a market cap of $110.12 million, a P/E ratio of -0.97 and a beta of 2.89. The firm's 50 day moving average is $2.26 and its 200 day moving average is $2.45. Tenaya Therapeutics has a 52-week low of $0.99 and a 52-week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07. Equities research analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.